BioSustane functions as a depot former for injectable drugs.
Injectable depot is usually subcutaneous or intramuscular, depositing the drug in a localized mass (or depot) from which it is gradually absorbed by surrounding tissue. This allows the active compound to be released in a consistent way over a long period of time, improving patient compliance.
Eastman BioSustane™ SAIB NF is an excellent lipophilic depot former. It is extensively metabolized in the body into sucrose and partially acylated sucrose, both readily absorbed and subsequently eliminated from the body. Release times can vary from a few days to a month or more.
Mechanism of release of API from BioSustane depot
Concept: On injection of a solution containing BioSustane, solvent, and API and optional additives, the small amount of solvent diffuses into surrounding tissue or interstitial fluid and leaves behind a highly viscous depot from which there is delayed release of active ingredient. The rate of breakdown of the depot can be slowed through the addition of an additive such as a biodegradable polymer.
Please note that, although BioSustane is being used by customers for injectable products or projects, Eastman does not currently market an injectable grade. It is the responsibility of the customer to make sure BioSustane meets injectable standard. Eastman does not have data through in-house studies for injectables; we are demonstrating that BioSustane has been used in injectables from publicly available information.